Spirulina and Angiogenesis

VEGF-VEGFR2 Axis

VEGF-A binds VEGFR2 on endothelial cells, activating PLCγ-PKC-MAPK and PI3K-AKT cascades that drive proliferation, migration, and survival. Pathological angiogenesis in tumors, diabetic retinopathy, and AMD involves sustained VEGF overexpression. Anti-VEGF therapy (bevacizumab, ranibizumab) is clinical standard for retinal disease.

HIF-1α and Hypoxia-Driven VEGF

HIF-1α stabilization (covered in glycolysis article) drives VEGF transcription. Tumors create hypoxic cores triggering HIF-VEGF axis activation and angiogenic recruitment. Spirulina reduces HIF-1α nuclear accumulation in chronic inflammation and metabolic disease, dampening pathological VEGF expression by 20-35%.

Context-Dependent Effects

Physiological angiogenesis in wound healing requires controlled VEGF; spirulina preserves this response. Pathological tumor angiogenesis requires sustained VEGF; spirulina suppresses it. The distinguishing variable is inflammation context. Spirulina's anti-inflammatory effects produce favorable VEGF modulation by normalizing the inflammatory context.

Diabetic Retinopathy Implications

Pathological retinal angiogenesis in diabetic retinopathy involves VEGF, HIF-1α, and inflammation. Spirulina's combined effects on glycemic control, HIF-1α stabilization reduction, and ocular inflammation provide multi-target modulation. Animal models show 25-35% reduction in retinal neovascularization with phycocyanin pretreatment.

Conclusion

Spirulina selectively suppresses pathological angiogenesis through HIF-1α reduction (20-35%), VEGF transcriptional dampening, and preserved physiological vessel response capacity. Clinical relevance spans diabetic retinopathy, AMD prevention, and theoretical cancer adjunct mechanisms. The context-dependency of spirulina's effects distinguishes it from broad-spectrum anti-VEGF agents.